Eliquis vs Trikafta
Side-by-side drug price comparison from Medicare Part D data
Verdict
Eliquis costs 96% less per claim than Trikafta ($510.00 vs $13935.00). Eliquis has a generic alternative available. Total Medicare spending: Eliquis at $16.6B vs Trikafta at $3.5B.
| Metric | Eliquis | Trikafta |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $510* | $13,935 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $16.6B | $3.5B |
| Total Claims | 32,460,000 | 248,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 14.2%* | 18.4% |
| Generic Available | Yes | Yes |
| Condition | Blood Clots | Cystic Fibrosis |
| Total Beneficiaries | 3,850,000 | 18,000 |
Eliquis costs 96% less per claim than Trikafta ($510.00 vs $13935.00). Eliquis has a generic alternative available. Total Medicare spending: Eliquis at $16.6B vs Trikafta at $3.5B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Eliquis and Trikafta. What follows is the interpretation — which specific axes carry the most weight for Eliquis versus Trikafta, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.